Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab and Vedolizumab in IBD (Phen_IBD)
NCT02694588Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jun 2014
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of infliximab and vedolizumab in inflammatory bowel disease (IBD) (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Mucosal healing at 2 weeks. Started Jun 2014; status: completed.
02
Drugs
infliximabvedolizumab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02694588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694588.